secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001193125-23-156642
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharmaceuticals appoints Tamar Thompson to Board; Board expands to 8 members
--------------------------------------------------------------------------------

- Tamar Thompson appointed to the Board effective May 25, 2023; Board size increased from 7 to 8.
- Thompson is VP, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Diseases.
- She brings over 20 years of experience in rare diseases, health policy, and government affairs.
- Previously served as Executive Director, State Govt Affairs & Federal Policy at Bristol-Myers Squibb.
- No family relationships or transactions with Catalyst exceeding $120,000 reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523156642/0001193125-23-156642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523156642/d511544d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-156642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer